Monthly Archives: April 2026

Biopharmaceutical manufacturing has undergone a significant transformation in recent years, driven by increasing regulatory expectations, complex production processes, and the need for greater efficiency. One of the most impactful developments supporting this evolution is the adoption of Digital Batch Records (DBRs), also commonly referred to as Electronic Batch Records (EBRs). Traditionally, pharmaceutical and biopharmaceutical

Advanced Therapy Medicinal Products (ATMPs) are rapidly transforming the pharmaceutical and biotechnology landscape. These therapies, which include gene therapies, cell therapies, and tissue-engineered products, offer groundbreaking treatments for conditions that previously had limited or no therapeutic options. As the number of ATMPs entering clinical development and commercial production continues to rise, regulatory authorities are

Cell and gene therapies (CGTs) represent one of the most transformative areas of modern medicine. These advanced therapies offer the potential to treat or even cure diseases that were previously considered untreatable, including certain cancers, genetic disorders, and rare diseases. However, the complexity of these therapies also presents unique manufacturing and quality challenges. Unlike

Quality by Design (QbD) has become a fundamental concept in modern pharmaceutical development and manufacturing. Rather than relying solely on end-product testing to ensure quality, QbD focuses on designing quality into products and processes from the earliest stages of development. First introduced by regulatory bodies such as the U.S. Food and Drug Administration (FDA)